



## Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October

September 28, 2020

DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and *in vivo* gene correction therapies with its ARCUS<sup>®</sup> genome editing platform, today announced its participation in the following upcoming virtual investor conferences:

- **Chardan 4<sup>th</sup> Annual Genetic Medicines Conference**

Date: Monday, October 5, 2020

Time: 8:30 – 9:00 AM ET

- **Jefferies Cell Therapy Summit**

Date: October 5, 2020

Time: 5:30 – 6:00 PM ET

Live webcasts of each presentation will be accessible on the Company's website [www.precisionbiosciences.com](http://www.precisionbiosciences.com), under the Investors & Media section. An archived replay of the webcasts will be available for approximately 30 days following the presentations.

### **About Precision BioSciences, Inc.**

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS<sup>®</sup> genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit [www.precisionbiosciences.com](http://www.precisionbiosciences.com).

### **Investor and Media Contact:**

Maurissa Messier

Senior Director, Corporate Communications

[maurissa.messier@precisionbiosciences.com](mailto:maurissa.messier@precisionbiosciences.com)

Josh Rappaport

Stern Investor Relations

[josh.rappaport@stern.com](mailto:josh.rappaport@stern.com)